A Comparison Of VEGF, SMRP, HE4and CA125Detection Value In Ovarian Cancer

Ovarian cancer is a common malignant tumor, clinical gynecology of its high incidence, accounting for2.4%～5.6%of female malignant tumor, because of its deep in the pelvic cavity, no specific symptoms early, late about70%of patients have been found, so early diagnosis difficult; Even if effective treatment, about70%of patients relapse after mitigation. So, early detection, early diagnosis, early treatment and postoperative effect of monitoring is the key to improve the patients survival rate, detection of tumor markers is of very important significance in the diagnosis and treatment, most scholars advocate using the method of combined detection of tumor markers, can make up for the shortage of the single detection, helps to improve the detection rate of tumor.A comparison of VEGF, SMRP, HE4and CA125detection value in ovarian cancerObjective:Research has shown that ovarian cancer incidence is rising trend year by year, every year for patients with ovarian cancer deaths in all kinds of female genital mutilation in patients with malignant tumor occupies the first place. So for the diagnosis and active treatment of ovarian cancer is a very important significance. At the molecular level to explore the mechanism of ovarian cancer, is a research hotspot in recent years. Is some biomarkers in the expression rate of abnormal lesions of the human body, so the test optional, in order to judge the pathological changes may, progress, and making treatment plan, etc. This study using vascular endothelial growth factor (VEGF) and serum of mesothelioma related protein (SMRP), human epididymis protein4(HE4) and transmembrane glycoprotein (CA125) test, observe the four roles in diagnosis and treatment of ovarian cancer, provide certain theoretical basis for the prevention and treatment of the disease. Preliminary analysis and express the relevance of the four, discuss the occurrence and development of the related molecular mechanism.Methods:Collected from January2010to December2013after pathologic diagnosis of ovarian cancer patients and patients with benign attachment lesions and normal physical examination of tissue samples for testing, the test results were retrospectively analyzed, it is divided into four groups of patients for ovarian cancer and benign lesion group and normal control group, The VEGF、SMRP、HE4level of58ovarian cancer patients,60ovarian benign tumorpatients and60healthy volunteers was was determined by a commercial ELISA assay,the kit, supplied by Fujirebio Diagnostics. Serum CA125concentration was routinely assayed by chemiluminescence. This study using statistical analysis of SPSS19.0data statistics processing. Between groups sample with x2test; Data conform to normality and homogeneity of variance using test statistical analysis, such as do not accord with normal distribution, the statistical analysis using Wilcoxon rank and inspection.Results:(1) the expression level of VEGF in ovarian cancer group was238.14±17.32pg/L, in the expression level of benign lesion group was189.32±16.38pg/L, were significantly higher than that of normal control group110.68±12.28pg/L (p<0.05). The expression in ovarian cancer and benign lesion group difference is not obvious, no statistical significance (p>0.05). The expression of CA125in the normal control group is lower, in the expression in ovarian cancer group compared with benign lesion group, there are obvious difference; HE4expression in ovarian cancer group is significantly higher than the other two groups, and in normal control group and benign lesions in the group expression difference is not obvious, there is no statistical significance (p>0.05); SMRP expression in observation group was obviously higher than that of other two groups, with statistical significance(P<0.05); In the expression of benign lesion group and normal control group no significant difference(P>0.05). Among them, the positive rate of CA125in ovarian cancer group (73.0%) were significantly higher than that of benign lesions group (19.0%) and normal controls (2.0%)(P<0.05), but the high false positive rate of benign lesion group, significantly higher than the other two groups (P<0.05).(2) the detection value of CA125in patients with ovarian cancer and chemotherapy after surgery four weeks after declined obviously, and the preoperative values have obvious difference (P<0.05), VEGF, SMRP, readings of HE4and four weeks after chemotherapy after surgery has decreased, but the three time points compared to the readings, and no significant difference (P>0.05). Have positive appeared in3cases of ovarian detection and is on the rise, after clinical tests such as CT, ultrasound or determine the pathology after surgery in tumor recurrence or metastasis.(3) in different pathological grading, the expression of HE4have obvious difference (P<0.05), while the expression of VEGF and SMRP and CA125were no obvious difference (P>0.05);(4) to detect the contents of serum marker of ovarian cancer alone or in combination, the sensitivity, specificity and accuracy comparison of joint detection accuracy were higher than single, but in terms of sensitivity and specificity, four joint detection and detect no difference alone, while HE4+CA125joint in these two aspects were significantly higher than that of single detection, indicates both the cost is low, and the accuracy, specificity and sensitivity are the most reasonable.Conclusion:VEGF in ovarian cancer group and in the expression level of benign lesion group were significantly higher than that of normal control group. And expression in ovarian cancer and benign lesion group difference is not obvious, its not as a single biological markers of ovarian cancer. HE4in different pathological grading, HE4expression have obvious difference, and the expression of VEGF and SMRP and CA125were no obvious difference, its in the staging of ovarian cancer has a good testing value. The positive rate of CA125in ovarian cancer group was significantly higher than that of benign lesions and normal controls, and the values after four weeks after surgery and chemotherapy significantly decreased, and the preoperative values have obvious difference, and there are3cases of ovarian tests is positive and is on the rise, after clinical tests such as CT, ultrasound or determine the pathology after surgery in tumor recurrence or metastasis, and discovered the recurrence of elevated CA125anomalies. But the detection of false positive rate is extremely high in the benign lesion group, significantly higher than the other two groups, so you need to combine with other markers, to select the most suitable markers, improve accuracy, sensitivity, specificity and detection results suggest HE4+CA125joint is in these two aspects were significantly higher than that of single detection, indicates both the cost is low, and the accuracy, specificity and sensitivity are the most reasonable.